Robust Immune Responses for Herpes Zoster Subunit Vaccine

MONDAY, May 21, 2018 -- Recipients of the herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01B Adjuvant System, develop robust immune responses, according to a study published in the June 1 issue...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

(MedPage Today) -- Vaccine development may help with prevention of herpes zoster in this population
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
Conditions:   Chronic Lymphocytic Leukemia (CLL);   Waldenstrom Macroglobulinemia (WM) Intervention:   Drug: Shingrix vaccine Sponsor:   University of Rochester Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The newly registered adjuvanted herpes zoster subunit vaccine (HZ/su) has a higher efficacy than the available live-attenuated vaccine (ZVL). National decision-makers soon need to decide whether to introduce H...
Source: BMC Medicine - Category: Internal Medicine Authors: Tags: Research article Source Type: research
Source: BMJ Comments - Category: General Medicine Source Type: forums
This study found a significantly increased zoster incidence in dermatomyositis and cutaneous lupus erythematosus compared with a control group.Physicians should be aware of this risk and consider administering the vaccine against zoster to these patients if not contraindicated.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
This report evaluates the fifth year of the shingles vaccination programme in England from 2017 to 2018.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
Introduction:Multiple myeloma (MM) is associated with end organ damage that negatively impacts the quality of life (QOL)and supportive care has a potential to improve symptoms.Methods:After detailed search on Pubmed, Cochrane, Embase and Clinical Trials.gov, we finalized total 36 articles on supportive care published after 2004.Results:Management of skeletal events: Mhaskar et al. (2017, n=3257) compared bisphosphonates (BPs) with placebo (PBO) in preventing pathological vertebral fractures, skeletal-related events (SRE), reported risk ratio (RR) of 0.74 in each; 95% CI 0.62-0.89 and 0.63-0.88 respectively. Both zoledronic...
Source: Blood - Category: Hematology Authors: Tags: 653. Myeloma: Therapy, excluding Transplantation: Poster I Source Type: research
IntroductionLymphoid neoplasms are among the most common hematologic malignancies. Viral infections are important causes of mortality and morbidity in patients with lymphoma. The majority of viral infectious complications in these patients result from the reactivation of various viruses such as Herpes Zoster (HZ). Most cases of HZ are self-limited; however, immunocompromised patients have a higher mortality rate from HZ and are at greater risk for recurrences and more serious and atypical complications.The most important established risk factors for developing HZ in cancer patients include neutropenia, duration and intensi...
Source: Blood - Category: Hematology Authors: Tags: 904. Outcomes Research-Malignant Conditions: Poster II Source Type: research
Immunization with Oka varicella vaccine reduces the incidence of herpes zoster (HZ) in vaccine recipients [1 –3], and universal varicella vaccination since October 2014 has reduced the HZ incidence in children aged 1 to 4 years in the Miyazaki Prefecture, Japan. The effect of universal varicella vaccination on the HZ incidence has been clarified by the Miyazaki study on HZ, which began in 1997 [4–6]. U niversal varicella vaccination increased the HZ incidence in the child-rearing generation by the loss of the chance to boost immunity to varicella-zoster virus [4].
Source: Journal of Dermatological Science - Category: Dermatology Authors: Tags: Letter to the Editor Source Type: research
THURSDAY, Nov. 8, 2018 -- The herpes zoster adjuvant recombinant subunit vaccine may be more effective than the live attenuated vaccine, though it is associated with an increased risk for adverse events at the injection site, according to a review...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Herpes | Pharmaceuticals | Shingles (Herpes Zoster) Vaccine | Study | Vaccines | Varicella-Zoster Virus Vaccine